Cargando…
Activation of CD8(+) T Cell Responses after Melanoma Antigen Targeting to CD169(+) Antigen Presenting Cells in Mice and Humans
The lack of tumor-reactive T cells is one reason why immune checkpoint inhibitor therapies still fail in a significant proportion of melanoma patients. A vaccination that induces melanoma-specific T cells could potentially enhance the efficacy of immune checkpoint inhibitors. Here, we describe a vac...
Autores principales: | van Dinther, Dieke, Lopez Venegas, Miguel, Veninga, Henrike, Olesek, Katarzyna, Hoogterp, Leoni, Revet, Mirjam, Ambrosini, Martino, Kalay, Hakan, Stöckl, Johannes, van Kooyk, Yvette, den Haan, Joke M. M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6406251/ https://www.ncbi.nlm.nih.gov/pubmed/30764534 http://dx.doi.org/10.3390/cancers11020183 |
Ejemplares similares
-
Comparison of Protein and Peptide Targeting for the Development of a CD169-Based Vaccination Strategy Against Melanoma
por: van Dinther, Dieke, et al.
Publicado: (2018) -
Optimization of Liposomes for Antigen Targeting to Splenic CD169(+) Macrophages
por: Nijen Twilhaar, Maarten K., et al.
Publicado: (2020) -
Antigen targeting reveals splenic CD169(+) macrophages as promoters of germinal center B‐cell responses
por: Veninga, Henrike, et al.
Publicado: (2015) -
Selective tumor antigen vaccine delivery to human CD169(+) antigen-presenting cells using ganglioside-liposomes
por: Affandi, Alsya J., et al.
Publicado: (2020) -
CD169 Defines Activated CD14(+) Monocytes With Enhanced CD8(+) T Cell Activation Capacity
por: Affandi, Alsya J., et al.
Publicado: (2021)